Bladder cancer is a very difficult disease to manage. Despite various types of surgical and systemic treatments, the oncological outcomes of bladder cancer are still unsatisfactory. Recently, there have been a lot of advances in the diagnosis and treatment of bladder cancer. Although cystoscopy is the gold standard in the primary diagnosis and surveillance of bladder cancer, urinary markers and MRI scans are likely to play an important role in the future. There are also newer surgical approaches that we should learn about in treating non-muscle-invasive and muscle-invasive bladder cancer. In addition, immunotherapy and novel agents have been increasingly investigated, not only in metastatic diseases, but also in earlier-stage bladder cancer. The aim of the current Research Topic is to cover promising, recent, and future research trends in the field of Bladder Cancer, with straightforward key messages for clinicians interested in this field.
The following topics will be discussed:
1. Urinary markers for bladder cancer – Current status and the future directions.
2. MRI and the VI-RADS scoring system for bladder cancer – What is the current evidence?
3. Quality performance indicators for transurethral resection of bladder tumour – Why are they important?
4. En bloc resection of bladder tumour – Is it the way forward?
5. Robotic-assisted radical cystectomy with intracorporeal urinary diversion – Is it justified?
6. Evidence on the extent of pelvic lymphadenectomy for muscle-invasive bladder cancer.
7. Novel agents for BCG-unresponsive non-muscle-invasive bladder cancer.
8. Neoadjuvant immunotherapy for muscle-invasive bladder cancer.
9. Optimising trimodality therapy for muscle-invasive bladder cancer.
10. Immunotherapy for advanced bladder cancer.
Bladder cancer is a very difficult disease to manage. Despite various types of surgical and systemic treatments, the oncological outcomes of bladder cancer are still unsatisfactory. Recently, there have been a lot of advances in the diagnosis and treatment of bladder cancer. Although cystoscopy is the gold standard in the primary diagnosis and surveillance of bladder cancer, urinary markers and MRI scans are likely to play an important role in the future. There are also newer surgical approaches that we should learn about in treating non-muscle-invasive and muscle-invasive bladder cancer. In addition, immunotherapy and novel agents have been increasingly investigated, not only in metastatic diseases, but also in earlier-stage bladder cancer. The aim of the current Research Topic is to cover promising, recent, and future research trends in the field of Bladder Cancer, with straightforward key messages for clinicians interested in this field.
The following topics will be discussed:
1. Urinary markers for bladder cancer – Current status and the future directions.
2. MRI and the VI-RADS scoring system for bladder cancer – What is the current evidence?
3. Quality performance indicators for transurethral resection of bladder tumour – Why are they important?
4. En bloc resection of bladder tumour – Is it the way forward?
5. Robotic-assisted radical cystectomy with intracorporeal urinary diversion – Is it justified?
6. Evidence on the extent of pelvic lymphadenectomy for muscle-invasive bladder cancer.
7. Novel agents for BCG-unresponsive non-muscle-invasive bladder cancer.
8. Neoadjuvant immunotherapy for muscle-invasive bladder cancer.
9. Optimising trimodality therapy for muscle-invasive bladder cancer.
10. Immunotherapy for advanced bladder cancer.
